Covalon Technologies Ltd Stock Price, News & Analysis

Covalon Technologies Ltd. (TSXV: COV, OTCQX: CVALF) has announced its participation in the 48th Annual Canadian Vascular Access Association (CVAA) Conference and World Congress on Vascular Access, taking place from April 26 to April 28, 2023, in Toronto, Canada. The conference will focus on advancements in infusion therapy and vascular access practices. Covalon aims to showcase its vascular access infection prevention solutions, including CovaClear IV, IV Clear, and VALGuard, designed to improve patient care and comfort. Senior VP Ron Hebert expressed enthusiasm about the opportunity to share insights on their innovative products that cater to both patients and healthcare providers. Attendees can visit Covalon’s booth for more information or connect via email for appointments.

Covalon Technologies Ltd. (TSXV:COV)(OTCQX:CVALF) will present at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 8:30 AM PDT. President and CEO Brian Pedlar will lead the presentation and answer questions afterward. Live access to the presentation can be found here.

Covalon specializes in advanced medical technologies, offering patented products that aim to protect patients from infections and facilitate healing. Their FDA-approved solutions are particularly beneficial for individuals dealing with chronic wounds or surgical recovery.

For those unable to attend the live session, all presentations will be available for viewing on the conference platform. Additionally, registered participants can schedule one-on-one meetings with Covalon representatives.

Covalon Technologies Ltd. (CVALF) is hosting a webinar titled "Protecting CVADs from Gross Contamination" on March 29, 2023, to combat the rising incidents of central line-associated bloodstream infections (CLABSIs), which have surged by 47% since the COVID-19 pandemic according to the CDC. The session, led by expert Matthew Ostroff, will discuss innovative solutions to prevent CLABSIs, particularly in pediatric healthcare settings. This webinar is part of Covalon's CLABSI Conscious campaign aimed at improving patient safety and reducing infection rates through advanced medical technology and expert guidance.

Covalon Technologies Ltd., trading under the symbol CVALF, recently announced its participation in the Synova NICU Leadership Forum from March 19 to March 23, 2023, in Tucson, Arizona. The company will showcase its innovative infection prevention solutions at booth 106, emphasizing compassion in patient care, particularly for NICU and pediatric patients. Covalon's products, like the CovaClear IV and VALGuard, aim to improve patient outcomes while reducing stress for healthcare providers. Six of the top ten children's hospitals have adopted these solutions.

Covalon Technologies Ltd. announced the results of its Fiscal 2022 Annual and Special Meeting of Shareholders held on March 8, 2023. Shareholders approved all matters including the election of the Board of Directors, the appointment of auditors, and the Omnibus Long-Term Incentive Plan. A total of 12,803,487 shares, or 51.076%, were represented at the meeting. Notable voting results included Amir Boloor receiving 92.275% support and PricewaterhouseCoopers receiving 99.996% approval as auditors. The detailed voting results will be filed on SEDAR with further information available in the management information circular dated February 1, 2023.